|
|
|
Insider
Information: |
Baker Felix |
Relationship: |
Director, 10% Owner |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
20 |
|
Direct
Shares |
927,207 |
|
Indirect Shares
|
141,861,898 |
|
|
Direct
Value |
$82,119,756 |
|
|
Indirect Value
|
$12,961,771,173 |
|
|
Total
Shares |
142,789,105 |
|
|
Total
Value |
$13,043,890,929 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
36
|
6
|
Stock
price went up :
|
15
|
6
|
Stock
price went down : |
21
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
6.0
|
Percentage
Gain/Loss : |
-24.3%
|
18.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Incyte Corp |
INCY |
Director, 10% Owner |
2023-09-29 |
559,963 |
2023-09-29 |
33,480,292 |
Premium* |
|
Ardea Biosciences Inc |
RDEA |
Director, 10% Owner |
2003-10-06 |
0 |
2012-02-01 |
116,454 |
Premium* |
|
Seagen Inc |
SGEN |
Director, 10% Owner |
2018-02-01 |
215,015 |
2018-02-01 |
44,355,335 |
Premium* |
|
Synageva BioPharma Corp |
GEVA |
Director, 10% Owner |
2015-06-22 |
100,503 |
2015-06-22 |
9,328,233 |
Premium* |
|
Viropharma Inc |
VPHM |
10% Owner |
2005-01-31 |
0 |
2011-12-14 |
303,264 |
Premium* |
|
Aceragen, Inc |
ACGN |
Director |
|
0 |
2017-07-03 |
145,453 |
Premium* |
|
Tapestry Pharmaceuticals Inc |
TPPHQ |
10% Owner |
|
0 |
2008-10-15 |
0 |
Premium* |
|
Genomic Health Inc |
GHDX |
Director, 10% Owner |
2012-10-01 |
288 |
2012-10-01 |
11,377,485 |
Premium* |
|
Allos Therapeutics Inc |
ALTH |
10% Owner |
|
0 |
2009-02-06 |
1,629 |
Premium* |
|
Biocryst Pharmaceuticals Inc |
BCRX |
10% Owner |
2016-08-16 |
46,918 |
2016-08-16 |
9,418,390 |
Premium* |
|
Heron Therapeutics Inc |
HRTX |
10% Owner |
|
0 |
2011-06-30 |
5,266,568 |
Premium* |
|
Adolor Corp |
ADLR |
10% Owner |
2010-04-26 |
0 |
2011-12-19 |
0 |
Premium* |
|
Diadexus Inc |
DDXS |
10% Owner |
|
0 |
2010-07-28 |
140,525 |
Premium* |
|
Pharmacyclics Inc |
PCYC |
10% Owner |
|
0 |
2011-08-22 |
1,809 |
Premium* |
|
Ocera Therapeutics Inc |
OCRX |
10% Owner |
2012-03-12 |
0 |
2012-03-14 |
57,704 |
Premium* |
|
XOMA Corporation |
XOMA |
Director, 10% Owner |
2012-10-29 |
0 |
2012-10-29 |
480,639 |
Premium* |
|
Neurogene |
NGNE |
10% Owner |
2015-08-07 |
4,520 |
|
0 |
Premium* |
|
Invitae Corp |
NVTA |
10% Owner |
|
0 |
2015-08-27 |
6,554,967 |
Premium* |
|
Bellicum Pharmaceuticals, Inc |
BLCM |
10% Owner |
|
0 |
2015-12-24 |
4,865,647 |
Premium* |
|
Kodiak Sciences Inc. |
KOD |
Director, 10% Owner |
2022-01-21 |
0 |
2022-06-06 |
15,967,504 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
1397 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 42 of 56
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
SGEN |
Seagen Inc |
Director |
|
2009-05-20 |
4 |
B |
$9.72 |
$342,659 |
I/I |
35,253 |
400,898 |
2.25 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2009-05-20 |
4 |
B |
$17.88 |
$635,637 |
I/I |
35,341 |
3,664,999 |
2.25 |
- |
|
ACGN |
Aceragen, Inc |
Director |
|
2017-07-03 |
4 |
A |
$1.75 |
$61,882 |
I/I |
35,361 |
145,453 |
0 |
- |
|
ALTH |
Allos Therapeutics Inc |
10% Owner |
|
2008-01-14 |
4 |
B |
$7.41 |
$262,521 |
I/I |
35,405 |
2,432,161 |
1.5 |
- |
|
RDEA |
Ardea Biosciences Inc |
10% Owner |
|
2007-01-25 |
4 |
B |
$6.00 |
$212,814 |
I/I |
35,469 |
1,000,982 |
1.5 |
- |
|
INCY |
Incyte Corp |
Director |
|
2008-01-09 |
4 |
B |
$10.94 |
$391,566 |
I/I |
35,783 |
3,020,572 |
2.25 |
- |
|
ALTH |
Allos Therapeutics Inc |
10% Owner |
|
2009-02-04 |
4 |
S |
$8.01 |
$305,386 |
I/I |
(36,586) |
228,113 |
0 |
- |
|
VPHM |
Viropharma Inc |
10% Owner |
|
2011-09-23 |
4 |
B |
$17.58 |
$651,492 |
I/I |
36,728 |
1,816,749 |
1.5 |
- |
|
ALTH |
Allos Therapeutics Inc |
10% Owner |
|
2008-05-22 |
4 |
B |
$5.64 |
$207,462 |
I/I |
36,784 |
264,699 |
1.5 |
- |
|
ACGN |
Aceragen, Inc |
10% Owner |
|
2008-07-17 |
4 |
S |
$14.80 |
$545,824 |
I/I |
(36,880) |
512,445 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2011-11-10 |
4 |
B |
$26.89 |
$993,654 |
I/I |
36,956 |
6,385,676 |
2.25 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2006-06-21 |
4 |
B |
$4.07 |
$150,643 |
I/I |
36,983 |
3,165,191 |
2.25 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2010-02-09 |
4 |
B |
$16.93 |
$632,501 |
I/I |
36,992 |
3,936,781 |
2.25 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2006-08-14 |
4 |
B |
$4.05 |
$150,134 |
I/I |
37,070 |
4,149,611 |
2.25 |
- |
|
GHDX |
Genomic Health Inc |
N/A |
|
2006-09-07 |
4 |
B |
$13.42 |
$500,916 |
I/I |
37,325 |
513,133 |
0.01 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2010-08-27 |
4 |
B |
$14.17 |
$541,502 |
I/I |
37,561 |
4,818,216 |
2.25 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2008-06-06 |
4 |
B |
$20.01 |
$760,813 |
I/I |
37,657 |
1,210,700 |
2.25 |
- |
|
ALTH |
Allos Therapeutics Inc |
10% Owner |
|
2008-01-11 |
4 |
B |
$7.47 |
$283,387 |
I/I |
37,921 |
6,380,478 |
1.5 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2008-02-11 |
4 |
B |
$9.06 |
$345,119 |
I/I |
38,112 |
7,640,538 |
2.25 |
- |
|
VPHM |
Viropharma Inc |
10% Owner |
|
2009-05-21 |
4 |
B |
$6.08 |
$231,912 |
I/I |
38,120 |
7,134,387 |
1.5 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2008-03-13 |
4 |
B |
$7.93 |
$304,356 |
I/I |
38,404 |
7,690,417 |
2.25 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2011-11-14 |
4 |
B |
$27.25 |
$1,066,091 |
I/I |
39,117 |
6,525,616 |
2.25 |
- |
|
RDEA |
Ardea Biosciences Inc |
10% Owner |
|
2005-07-14 |
4 |
B |
$3.50 |
$138,306 |
I/I |
39,516 |
435,854 |
1.5 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2008-01-18 |
4 |
B |
$9.00 |
$359,199 |
I/I |
39,911 |
360,409 |
2.25 |
- |
|
INCY |
Incyte Corp |
Director |
|
2022-03-08 |
4 |
OE |
$22.05 |
$882,000 |
I/I |
40,000 |
33,059,604 |
0 |
- |
|
1397 Records found
|
|
Page 42 of 56 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|